Guidelines for the diagnosis and management of disseminated intravascular coagulation

British Journal of Haematology

Volumn 145, Issue 1, 2009, Pages 24-33

  Levi, M ^a   Toh, C H ^b,c,d   Thachil, J ^b   Watson, H G ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d BCSH Secretary   (United Kingdom)

Author keywords

Anticoagulation; Blood coagulation; Coagulation factors; Disseminated intravascular coagulation; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CRYOPRECIPITATE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FULMINATING PURPURA; HIGH RISK PATIENT; HUMAN; HYPOFIBRINOGENEMIA; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PATIENT MONITORING; PLASMA TRANSFUSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT RESPONSE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMATOLOGIC TESTS; HEMOSTASIS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS;

EID: 61849136778     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07600.x     Document Type: Article

References (70)

1. Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal Nogare, A., Postier, R., Hempelmann, G., Butler, T., Martin, E., Zwingelstein, C., Percell, S., Shu, V., Leighton, A. Creasey, A.A. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Critical Care Medicine, 29, 2081 2089.
2. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., Beale, R., Svoboda, P., Laterre, P.F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Artigas, A., Percell, S.R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J.C. Creasey, A.A. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290, 238 247.
3. Abraham, E., Laterre, P.F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B.L., Francois, B., Guy, J.S., Bruckmann, M., Rea-Neto, A., Rossaint, R., Perrotin, D., Sablotzki, A., Arkins, N., Utterback, B.G. Macias, W.L. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine, 353, 1332 1341.
4. Akca, S., Haji-Michael, P., de, M.A., Suter, P., Levi, M. Vincent, J.L. (2002) Time course of platelet counts in critically ill patients. Critical Care Medicine, 30, 753 756.
5. Al-Mondhiry, H. (1975) Disseminated intravascular coagulation: experience in a major cancer center. Thrombosis et Diathesis Haemorrhagica, 34, 181 193.
6. Angstwurm, M.W., Dempfle, C.E. Spannagl, M. (2006) New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with acute physiology and chronic health evaluation II and logistic organ dysfunction scores. Critical Care Medicine, 34, 314 320.
7. Asakura, H., Ontachi, Y., Mizutani, T., Kato, M., Ito, T., Saito, M., Morishita, E., Yamazaki, M., Aoshima, K., Takami, A., Yoshida, T., Suga, Y., Miyamoto, K. Nakao, S. (2001) Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. European Journal of Haematology, 67, 170 175.
8. Audibert, G., Lambert, H., Toulemonde, F., Alexandre, P., Laprevote-Heully, M.C., Bollaert, P.E., Bauer, P. Larcan, A 1987) Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy. Journal des Maladies Vasculaires, 12 (Suppl B 147 151 [French].
9. Avvisati, G., ten Cate, J.W., Buller, H.R. Mandelli, F. (1989) Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet, 2, 122 124.
10. Bakhtiari, K., Meijers, J.C., de, J.E. Levi, M. (2004) Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Critical Care Medicine, 32, 2416 2421.
11. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W. Fisher, C.J.J. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine, 344, 699 709.
12. Bernard, G.R., Macias, W.L., Joyce, D.E., Williams, M.D., Bailey, J. Vincent, J.L. (2003) Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Critical Care, 7, 155 163.
13. Bernard, G.R., Margolis, B.D., Shanies, H.M., Ely, E.W., Wheeler, A.P., Levy, H., Wong, K. Wright, T.J. (2004) Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest, 125, 2206 2216.
14. Bick, R.L. (1996) Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Seminars in Thrombosis & Hemostasis, 22, 69 88.
15. Bick, R.L. Baker, W.F. (1992) Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thrombosis Research, 65, 785 790.
16. Boisclair, M.D., Ireland, H. Lane, D.A. (1990) Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Reviews, 4, 25 40.
17. Brown, J.E., Olujohungbe, A., Chang, J., Ryder, W.D., Morganstern, G.R., Chopra, R. Scarffe, J.H. (2000) All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. British Journal of Haematology, 110, 1010 1012.
18. Carr, J.M., McKinney, M. McDonagh, J. (1989) Diagnosis of disseminated intravascular coagulation. Role of D-dimer. American Journal of Clinical Pathology, 91, 280 287.
19. Cauchie, P., Cauchie, C., Boudjeltia, K.Z., Carlier, E., Deschepper, N., Govaerts, D., Migaud-Fressart, M., Woodhams, B. Brohee, D. (2006) Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital - meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. American Journal of Hematology, 81, 414 419.
20. Collins, P.W., Macchiavello, L.I., Lewis, S.J., Macartney, N.J., Saayman, A.G., Luddington, R., Baglin, T. Findlay, G.P. (2006) Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. British Journal of Haematology, 135, 220 227.
21. Conway, E.M. Rosenberg, R.D. (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Molecular and Cellular Biology, 8, 5588 5592.
22. Cook, D.J., Crowther, M.A., Meade, M.O. Douketis, J. (2005) Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. Journal of Critical Care, 20, 309 313.
23. Corrigan, J.J.J. Jordan, C.M. (1970) Heparin therapy in septicemia with disseminated intravascular coagulation. New England Journal of Medicine, 283, 778 782.
24. De Pont, A.C., Bakhtiari, K., Hutten, B.A., de Jonge, E., Vroom, M.B., Meijers, J.C., Buller, H.R. Levi, M. (2005) Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. Critical Care, 9, R490 R497.
25. Dempfle, C.E., Zips, S., Ergul, H. Heene, D.L. (2001) The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer. Journal of Thrombosis and Haemostasis, 86, 1204 1209.
26. Dempfle, C.E., Wurst, M., Smolinski, M., Lorenz, S., Osika, A., Olenik, D., Fiedler, F. Borggrefe, M. (2004a) Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Journal of Thrombosis and Haemostasis, 91, 812 818.
27. Dempfle, C.E., Lorenz, S., Smolinski, M., Wurst, M., West, S., Houdijk, W.P., Quintel, M. Borggrefe, M. (2004b) Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Critical Care Medicine, 32, 520 524.
28. Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettila, V., Basson, B.R., Brandt, J.T., Sundin, D. Levi, M. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2, 1924 1933.
29. Downey, C., Kazmi, R. Toh, C.H. (1997) Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. British Journal of Haematology, 98, 68 73.
30. Downey, C., Kazmi, R. Toh, C.H. (1998) Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Journal of Thrombosis and Haemostasis, 80, 65 69.
31. Faust, S.N., Levin, M., Harrison, O.B., Goldin, R.D., Lockhart, M.S., Kondaveeti, S., Laszik, Z., Esmon, C.T. Heyderman, R.S. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New England Journal of Medicine, 345, 408 416.
32. Feinstein, D.I. (1988) Treatment of disseminated intravascular coagulation. [Review] [122 refs]. Seminars in Thrombosis & Hemostasis, 14, 351 362.
33. Fourrier, F., Chopin, C., Goudemand, J., Hendrycx, S., Caron, C., Rime, A., Marey, A. Lestavel, P. (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest, 101, 816 823.
34. Gando, S., Wada, H., Asakura, H., Iba, T., Eguchi, Y., Okamoto, K., Ohtomo, Y., Kawasugi, K., Koga, S., Koseki, K., Tsuji, H., Mayumi, T., Murata, A., Nakagawa, M. Endo, S. (2005) Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clinical and Applied Thrombosis/Hemostasis, 11, 71 76.
35. Horan, J.T. Francis, C.W. (2001) Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Seminars in Thrombosis & Hemostasis, 27, 657 666.
36. Kienast, J., Juers, M., Wiedermann, C.J., Hoffmann, J.N., Ostermann, H., Strauss, R., Keinecke, H.O., Warren, B.L. Opal, S.M. (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 4, 90 97.
37. Levi, M. (2004) Current understanding of disseminated intravascular coagulation. British Journal of Haematology, 124, 567 576.
38. Levi, M. (2005) Disseminated intravascular coagulation: what's new? Critical Care Clinics, 21, 449 467.
39. Levi, M. Opal, S.M. (2006) Coagulation abnormalities in critically ill patients. Critical Care, 10, 222.
40. Levi, M. Ten, C.H. (1999) Disseminated intravascular coagulation. New England Journal of Medicine, 341, 586 592.
41. Levi, M., de, J.E., van der, P.T. Ten, C.H. (1999) Disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 82, 695 705.
42. Levi, M., Levy, M., Williams, M.D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F.V., Wang, D., Sundin, D.P. Macias, W.L. (2007) Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). American Journal of Respiratory and Critical Care Medicine, 176, 483 490.
43. Mackie, I.J., Kitchen, S., Machin, S.J. Lowe, G.D. (2003) Guidelines on fibrinogen assays. British Journal of Haematology, 121, 396 404.
44. Mannucci, P.M. Levi, M. (2007) Prevention and treatment of major blood loss. New England Journal of Medicine, 356, 2301 2311.
45. Mant, M.J. King, E.G. (1979) Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. American Journal of Medicine, 67, 557 563.
46. Matsumoto, T., Wada, H., Nishioka, Y., Nishio, M., Abe, Y., Nishioka, J., Kamikura, Y., Sase, T., Kaneko, T., Houdijk, W.P., Nobori, T. Shiku, H. (2006) Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. Clinical and Applied Thrombosis/hemostasis, 12, 185 192.
47. McCarron, B.I., Marder, V.J. Francis, C.W. (1999) Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Journal of Thrombosis and Haemostasis, 82, 1722 1729.
48. Mesters, R.M., Mannucci, P.M., Coppola, R., Keller, T., Ostermann, H. Kienast, J. (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood, 88, 881 886.
49. Mongan, P.D. Hosking, M.P. (1992) The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology, 77, 38 46.
50. Nakamura, Y., Tomura, S., Tachibana, K., Chida, Y. Marumo, F. (1992) Enhanced fibrinolytic activity during the course of hemodialysis. Clinical Nephrology, 38, 90 96.
51. Neame, P.B., Kelton, J.G., Walker, I.R., Stewart, I.O., Nossel, H.L. Hirsh, J. (1980) Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood, 56, 88 92.
52. Olson, J.D., Kaufman, H.H., Moake, J., O'Gorman, T.W., Hoots, K., Wagner, K., Brown, C.K. Gildenberg, P.L. (1989) The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery, 24, 825 832.
53. Patel, R., Cook, D.J., Meade, M.O., Griffith, L.E., Mehta, G., Rocker, G.M., Marshall, J.C., Hodder, R., Martin, C.M., Heyland, D.K., Peters, S., Muscedere, J., Soth, M., Campbell, N. Guyatt, G.H. (2005) Burden of illness in venous thromboembolism in critical care: a multicenter observational study. Journal of Critical Care, 20, 341 347.
54. Pernerstorfer, T., Hollenstein, U., Hansen, J., Knechtelsdorfer, M., Stohlawetz, P., Graninger, W., Eichler, H.G., Speiser, W. Jilma, B. (1999) Heparin blunts endotoxin-induced coagulation activation. Circulation, 100, 2485 2490.
55. Prisco, D., Paniccia, R., Bonechi, F., Francalanci, I., Abbate, R. Gensini, G.F. (1989) Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products. Thrombosis Research, 56, 547 551.
56. Samama, M.M., Cohen, A.T., Darmon, J.Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.G., Turpie, A.G. Weisslinger, N. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. New England Journal of Medicine, 341, 793 800.
57. de la Serna, J., Montesinos, P., Vellenga, E., Rayon, C., Parody, R., Leon, A., Esteve, J., Bergua, J.M., Milone, G., Deben, G., Rivas, C., Gonzalez, M., Tormo, M., az-Mediavilla, J., Gonzalez, J.D., Negri, S., Amutio, E., Brunet, S., Lowenberg, B. Sanz, M.A. (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 111, 3395 3402.
58. Shorr, A.F., Trotta, R.F., Alkins, S.A., Hanzel, G.S. Diehl, L.F. (1999) D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Medicine, 25, 207 210.
59. Siegal, T., Seligsohn, U., Aghai, E. Modan, M. (1978) Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Journal of Thrombosis and Haemostasis, 39, 122 134.
60. Sivula, M., Tallgren, M. Pettila, V. (2005) Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Medicine, 31, 1209 1214.
61. Spero, J.A., Lewis, J.H. Hasiba, U. (1980) Disseminated intravascular coagulation. Findings in 346 patients. Journal of Thrombosis and Haemostasis, 43, 28 33.
62. Taylor, F.B.J., Chang, A., Esmon, C.T., D'Angelo, A., Vigano-D'Angelo, S. Blick, K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. Journal of Clinical Investigation, 79, 918 925.
63. Taylor, F.B., Jr., Toh, C.H., Hoots, W.K., Wada, H. Levi, M 2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis., 86, 1327 1330.
64. Toh, C.H. Dennis, M. (2003) Disseminated intravascular coagulation: old disease, new hope. BMJ, 327, 974 977.
65. Toh, C.H. Hoots, W.K. (2007) The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. Journal of Thrombosis and Haemostasis, 5, 604 606.
66. Toh, C.H., Downey, C. Dwyre, L. (2000) Thromboplastin sensitivity in waveform analysis. Journal of Thrombosis and Haemostasis, 84, 517 518.
67. Wada, H., Wakita, Y., Nakase, T., Shimura, M., Hiyoyama, K., Nagaya, S., Mori, Y. Shiku, H. (1995) Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Journal of Thrombosis and Haemostasis, 74, 848 852.
68. Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., Knaub, S., Keinecke, H.O., Heinrichs, H., Schindel, F., Juers, M., Bone, R.C. Opal, S.M. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA, 286, 1869 1878.
69. Wilde, J.T., Kitchen, S., Kinsey, S., Greaves, M. Preston, F.E. (1989) Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. British Journal of Haematology, 71, 65 70.
70. Zuckerman, L., Cohen, E., Vagher, J.P., Woodward, E. Caprini, J.A. (1981) Comparison of thrombelastography with common coagulation tests. Journal of Thrombosis and Haemostasis, 46, 752 756.